sellModerate cluster of 610b5-1 plan
Wang Lai sold $1.3M of ONC
Global Head of R&D at BeOne Medicines Ltd.. 5,000 shares at an average of $257.23, traded Feb 21, 2025, filed Feb 25, 2025.
Warning score
55Value
$1.3M
5,000 shares
Holdings after
0
-100% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001651308-25-000021, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -1,327 | $254.82 | $338k | 3,673 | Feb 25, 2025 |
| Feb 21, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -575 | $255.86 | $147k | 3,098 | Feb 25, 2025 |
| Feb 21, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -479 | $256.70 | $123k | 2,619 | Feb 25, 2025 |
| Feb 21, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -437 | $258.18 | $113k | 2,182 | Feb 25, 2025 |
| Feb 21, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -1,782 | $258.73 | $461k | 400 | Feb 25, 2025 |
| Feb 21, 2025 | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -400 | $260.17 | $104k | 0 | Feb 25, 2025 |
Related signals
Other insiders at BeOne Medicines Ltd. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 25Weak | sell10b5-1 | ONC BeOne Medicines Ltd. | Wang Xiaodong director, other | $11M | 31,028 | |
| 33Weak | sell 210b5-1 | ONC BeOne Medicines Ltd. | Wang Xiaodong director, other | $13M | 38,287 | |
| 49Moderate | sell 2 | ONC BeOne Medicines Ltd. | Ball Titus B. Principal Accounting Officer | $47k | 132 | |
| 40Moderate | sell 310b5-1 | ONC BeOne Medicines Ltd. | Wang Xiaodong director, other | $11M | 41,760 | |
| 70Notable | sell 5 | ONC BeOne Medicines Ltd. | OYLER JOHN Chief Executive Officer | $10M | 41,210 | |
| 45Moderate | sell 610b5-1 | ONC BeOne Medicines Ltd. | Wu Xiaobin President, COO & GM China | $14M | 51,921 | |
| 70Notable | sell 6 | ONC BeOne Medicines Ltd. | OYLER JOHN Chief Executive Officer | $10M | 40,109 | |
| 70Notable | sell 6 | ONC BeOne Medicines Ltd. | OYLER JOHN Chief Executive Officer | $15M | 58,590 | |
| 55Moderate | sell 610b5-1 | ONC BeOne Medicines Ltd. | Wang Xiaodong director, other | $2.1M | 8,146 | |
| 70Notable | sell 6 | ONC BeOne Medicines Ltd. | OYLER JOHN Chief Executive Officer | $25M | 101,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.